Scarica l'app Stockscreener
94.14
0.17%
0.2064
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BNTX Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$93.93
Aprire:
$94.41
Volume 24 ore:
537.27K
Relative Volume:
0.57
Capitalizzazione di mercato:
$23.81B
Reddito:
$3.26B
Utile/perdita netta:
$-1.45B
Rapporto P/E:
-16.03
EPS:
-5.871
Flusso di cassa netto:
$1.18B
1 W Prestazione:
+1.11%
1M Prestazione:
+6.82%
6M Prestazione:
-5.99%
1 anno Prestazione:
-14.50%
Intervallo 1D:
$93.35
$95.06
Intervallo di 1 settimana:
$92.56
$98.81
Portata 52W:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
94.15 | 23.75B | 3.26B | -1.45B | 1.18B | -5.871 |
VRTX
Vertex Pharmaceuticals Inc
|
522.00 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.79 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.13 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.99 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.13 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-06-05 | Reiterato | H.C. Wainwright | Buy |
| 2025-05-29 | Iniziato | Goldman | Neutral |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-01-10 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-02 | Reiterato | BMO Capital Markets | Outperform |
| 2024-11-19 | Iniziato | Berenberg | Buy |
| 2024-11-19 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-09-24 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-09-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-14 | Iniziato | Evercore ISI | In-line |
| 2024-02-23 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-05 | Iniziato | Oppenheimer | Perform |
| 2023-12-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-17 | Aggiornamento | Redburn | Neutral → Buy |
| 2022-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-08-17 | Iniziato | Cowen | Market Perform |
| 2022-07-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2021-12-16 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Iniziato | Deutsche Bank | Hold |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-08-11 | Aggiornamento | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-06-16 | Downgrade | Redburn | Neutral → Sell |
| 2021-05-18 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-08-03 | Ripresa | Berenberg | Buy |
| 2020-07-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-30 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Iniziato | H.C. Wainwright | Neutral |
| 2020-01-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Downgrade | UBS | Buy → Neutral |
| 2019-11-05 | Iniziato | Wolfe Research | Outperform |
| 2019-11-04 | Iniziato | Berenberg | Buy |
| 2019-11-04 | Iniziato | BofA/Merrill | Buy |
| 2019-11-04 | Iniziato | Canaccord Genuity | Buy |
| 2019-11-04 | Iniziato | JP Morgan | Overweight |
| 2019-11-04 | Iniziato | SVB Leerink | Outperform |
| 2019-11-04 | Iniziato | UBS | Buy |
Mostra tutto
Biontech Se Adr Borsa (BNTX) Ultime notizie
10 Newly Overvalued Stocks this Week - Morningstar
BioNTech’s Factory Sell-Off and a Founder’s Spin-Off: Two Bets That Could Reshape the Stock - aktiencheck.de
PTC Therapeutics (PTCT) moves 7.2% higher: Will this strength last? - MSN
MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week? - TradingView
BioNTech SE ADR (BNTX) News Today: Latest Market and Industry Updates - Traders Union
BioNTech stock trades down as founders leave the company, raising transition concerns - Traders Union
Comirnaty Omicron-adapted formulation from BioNTech SEupdated mRNA shot for the 2024-25 season - AD HOC NEWS
Enterprise value to revenue forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
BioNTech SE Sponsored ADR Actuals & Estimates (NASDAQ:BNTX) - TradingView
Price to sales forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
Enterprise value to EBIT forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
BioNTech’s Oncology Transformation Hinges on Dense Second-Half Data Flow () - aktiencheck.de
BioNTech (BNTX) 10K Form and Latest SEC Filings 2026 - MarketBeat
Price to earnings forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
Ubiquiti Upgraded, Reddit Downgraded: Updated Rankings on Top Blue-Chip Stocks - Yahoo Finance
BioNTech's €16.8 Billion Cash Hoard Is the Prize as Moderna Circles Factories and Spin-Off Looms - aktiencheck.de
Why BioNTech’s BNT316/ ONC-392 could quietly change lung cancer care - Ad-hoc-news.de
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - Yahoo Finance
BioNTech Faces Shareholder Revolt Over Spin-Off Even as It Prepares First US Cancer Filing - aktiencheck.de
BioNTech Slashes 1,800 Jobs and Kicks Off $1 Billion Buyback in Oncology Push () - aktiencheck.de
BioNTech SE Stock (US09075V1026): Buyback And Oncology Pipeline Keep Shares In Focus - Ad-hoc-news.de
BioNTech Stands at a Pivotal Juncture as First FDA Filing Approaches and Pipeline Data Piles Up - aktiencheck.de
Moderna Says New COVID Vax Doesn't Infringe BioNTech IP - Law360
BioNTech's $1 Billion Buyback Marches Forward as Founders Exit and Cancer Trials Intensify - aktiencheck.de
BioNTech Has $16.8 Billion in Cash, a $1 Billion Buyback, and Promising Cancer Data — So Why Is the Stock Stuck? - aktiencheck.de
BioNTech: When Pipeline Progress Meets a Market That Demands Revenue () - aktiencheck.de
Comirnaty COVID-19 Vaccine: What Matters Now for US Patients - AD HOC NEWS
Bristol-Myers Upgraded, Broadcom Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech’s Pipeline Pivot Meets a Market That Won’t Look Up () - aktiencheck.de
BioNTech Stock: A Week of Crosscurrents Where Macro and a Medical Congress Collide () - aktiencheck.de
BioNTech Faces Twin Headwinds: Analyst Divergence and German Health Overhaul () - aktiencheck.de
Bernstein reiterates BioNTech stock rating on pumitamig risks - Investing.com
BioNTech's Oncology Momentum Clashes With Berlin's Health-Cost Crackdown () - aktiencheck.de
BioNTech’s Costly Pivot: Cancer Pipeline Promises Meet Political and Financial Realities () - aktiencheck.de
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer - news.financial
BioNTech's ASCO Data Showcase Two Late-Stage Hopes Amid Cost Cuts and a $1 Billion Buyback - aktiencheck.de
BNTX Technical Analysis | Trend, Signals & Chart Patterns | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
BioNTech Races Toward First Oncology Approval as ASCO Data Bolsters Pipeline Credibility - aktiencheck.de
BNTX Stock Quote Price and Forecast - CNN
Pumitamig’s 72.7% Response at Reduced Dose Reshapes BioNTech’s Oncology Ambitions () - aktiencheck.de
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial - GlobeNewswire Inc.
BioNTech Juggles Vaccine Tweaks and Cancer Milestones as Investors Look Beyond COVID - aktiencheck.de
BioNTech Shows Its Hand at ASCO: A Pipeline in Full Bloom and a Radical Cost Overhaul () - aktiencheck.de
BNTXBioNTech SE ADR Dividends - Finviz
BioNTech upgraded to “buy” at UBS as next-gen cancer drugs de-risk - Investing.com
Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock? - news.financial
BioNTech Grapples With Labor Strife and Analyst Skepticism as Stock Languishes () - aktiencheck.de
BioNTech’s ASCO Runway: Dual Cancer Data, a Shifting Analyst Pulse, and a Cash-Rich Pause for Growth - aktiencheck.de
BioNTech Faces Twin Test: Labor Strife Over 1,860 Jobs Meets ASCO’s Clinical Verdict () - aktiencheck.de
BioNTech Unveils $1B Buyback While Bernstein Flags Approval Risk Ahead of Oncology Data Dump - aktiencheck.de
BioNTech’s ctDNA Colorectal Cancer Study Signals Next Steps in Its Oncology Strategy - TipRanks
Biontech Se Adr Azioni (BNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Biontech Se Adr Azioni (BNTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Poetting Sierk | Chief Operating Officer |
Apr 22 '26 |
Sale |
110.56 |
50,000 |
5,527,960 |
399,387 |
1.21%
3.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):